Marine Sulfated Polysaccharide PMGS Synergizes with Paclitaxel in Inhibiting Cervical Cancer In Vitro

Mar Drugs. 2023 Apr 23;21(5):259. doi: 10.3390/md21050259.

Abstract

The incidence and mortality of cervical cancer in female malignancies are second only to breast cancer, which brings a heavy health and economic toll worldwide. Paclitaxel (PTX)-based regimens are the first-class choice; however, severe side effects, poor therapeutic effects, and difficulty in effectively preventing tumor recurrence or metastasis are unavoidable. Therefore, it is necessary to explore effective therapeutic interventions for cervical cancer. Our previous studies have shown that PMGS, a marine sulfated polysaccharide, exhibits promising anti-human papillomavirus (anti-HPV) effects through multiple molecular mechanisms. In this article, a continuous study identified that PMGS, as a novel sensitizer, combined with PTX exerted synergistic anti-tumor effects on cervical cancer associated with HPV in vitro. Both PMGS and PTX inhibited the proliferation of cervical cancer cells, and the combination of PMGS with PTX displayed significant synergistic effects on Hela cells. Mechanistically, PMGS synergizes with PTX by enhancing cytotoxicity, inducing cell apoptosis and inhibiting cell migration in Hela cells. Collectively, the combination of PTX and PMGS potentially provides a novel therapeutic strategy for cervical cancer.

Keywords: cervical cancer; marine sulfated polysaccharides; paclitaxel; synergistic effect.

MeSH terms

  • Apoptosis
  • Cell Line, Tumor
  • Female
  • HeLa Cells
  • Humans
  • Paclitaxel* / pharmacology
  • Paclitaxel* / therapeutic use
  • Polysaccharides / pharmacology
  • Polysaccharides / therapeutic use
  • Sulfates / pharmacology
  • Uterine Cervical Neoplasms* / drug therapy
  • Uterine Cervical Neoplasms* / pathology

Substances

  • Paclitaxel
  • Sulfates
  • Polysaccharides